Why Is Larimar Therapeutics Stock Trading Lower On Monday?
| LRMR Stock | USD 4.32 0.51 10.56% |
Slightly above 62% of Larimar Therapeutics' investor base is looking to short. The analysis of the overall investor sentiment regarding Larimar Therapeutics suggests that many traders are alarmed. Larimar Therapeutics' investing sentiment overview a quick insight into current market opportunities from investing in Larimar Therapeutics. Many technical investors use Larimar Therapeutics stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Larimar |
On Monday, Larimar Therapeutics, Inc. released initial data from the ongoing long-term OLE study evaluating daily subcutaneous injections of 25 mg of nomlabofusp self-administered or administered by a caregiver in participants with Friedreichs Ataxia. Friedreichs Ataxia is caused by a mutation in the FXN gene, which carries the code for the frataxin protein. Frataxin is important for the normal function of mitochondria, the energy-producing parts of cells At the time of data cut
Read at finance.yahoo.com
 |
Larimar Therapeutics Fundamental Analysis
We analyze Larimar Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Larimar Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Larimar Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Target Price
Target Price Comparative Analysis
Larimar Therapeutics is currently under evaluation in target price category among its peers.
Larimar Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Larimar Therapeutics stock to make a market-neutral strategy. Peer analysis of Larimar Therapeutics could also be used in its relative valuation, which is a method of valuing Larimar Therapeutics by comparing valuation metrics with similar companies.
Peers
Larimar Therapeutics Related Equities
| IMRX | Immuneering Corp | 5.49 | ||||
| MRUS | Merus BV | 4.91 | ||||
| CNTA | Centessa Pharmaceuticals | 1.09 | ||||
| STRO | Sutro Biopharma | 0.97 | ||||
| CHRS | Coherus BioSciences | 0.59 | ||||
| PCVX | Vaxcyte | 0.41 | ||||
| CELC | Celcuity LLC | 0.24 | ||||
| DAWN | Day One | 0.16 | ||||
| KZR | Kezar Life | 0.91 | ||||
| SNDX | Syndax Pharmaceuticals | 1.16 | ||||
| BOLT | Bolt Biotherapeutics | 1.89 | ||||
| IKNA | Ikena Oncology | 2.42 | ||||
| CABA | Cabaletta Bio | 2.48 | ||||
| SPRO | Spero Therapeutics | 3.74 | ||||
| ALEC | Alector | 4.06 | ||||
| SRZN | Surrozen | 4.80 | ||||
| KROS | Keros Therapeutics | 7.31 |
Additional Tools for Larimar Stock Analysis
When running Larimar Therapeutics' price analysis, check to measure Larimar Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Larimar Therapeutics is operating at the current time. Most of Larimar Therapeutics' value examination focuses on studying past and present price action to predict the probability of Larimar Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Larimar Therapeutics' price. Additionally, you may evaluate how the addition of Larimar Therapeutics to your portfolios can decrease your overall portfolio volatility.